key: cord-0869268-tvvbda2k
authors: Douillet, Delphine; Riou, Jérémie; Penaloza, Andrea; Moumneh, Thomas; Soulie, Caroline; Savary, Dominique; Morin, Francois; Mahieu, Rafaël; Roy, Pierre-Marie
title: Risk of symptomatic venous thromboembolism in mild and moderate COVID-19: A comparison of two prospective European cohorts
date: 2021-10-08
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.10.001
sha: fa932ba2abbae3d7558f67ef7ace0f51995d5d82
doc_id: 869268
cord_uid: tvvbda2k

BACKGROUND: Severely ill patients with SARS-CoV-2 have an increased risk of venous thromboembolism (VTE) i.e., deep vein thrombosis and pulmonary embolism, However, the VTE risk in patients with mild and moderate COVID-19, hospitalized or managed at home, remain uncertain. The aims of this study were to assess the rate and the risk factors symptomatic VTE, in patients with mild and moderate COVID-19 and to compare them to a cohort of similar patients without COVID-19. METHODS: Patients presenting to the emergency department (ED) of participating centers for confirmed or probable mild or moderate COVID-19 and not having acute VTE were included. This COVID-19 cohort was retrospectively compared to a prospective cohort of similar ED patients using propensity score matching. The main outcome was the rate of symptomatic VTE within the 28 days after ED presentation. RESULTS: A total of 2292 patients were included in the COVID-19 cohort. The 28-day incidence of symptomatic VTE was 1.3% (n = 29/2292, 95%CI: 0.9 to 1.8), 2.3% (n = 20/866, 95%CI: 1.5 to 3.5) in moderate COVID-19 patients and 0.6% (n = 9/1426; 95%CI: 0.3 to 1.2) in mild COVID-19 patients managed as outpatients. An age over 65 years and hospitalization were independent risk factors of VTE. After adjustment, patients in the COVID-19 cohort had an absolute increase in over symptomatic VTE risk of +1.69% (95%CI, 0.88 to 2.51) versus patients in the comparison cohort (n = 1539). CONCLUSIONS: Patients with moderate COVID-19 presenting to the ED had a high risk of subsequent VTE. TRIAL REGISTRATION: Ethics committee of the CHU of Angers (N°2020/87).

The coronavirus disease 2019 (COVID-19) viral pneumonia leads to hypoxia, a hyperinflammatory state and immunothrombosis. A complex interaction between coagulopathy, thrombocytopathy and endotheliopathy contributes to COVID-19-associated thromboinflammation 1 . The initial reports from hospitals in Wuhan, China, showed that patients with severe COVID-19 had higher levels of D-dimer 2,3 . Subsequently, COVID-19 was reported to be associated with a high risk of venous thromboembolism (VTE), especially in critically ill patients [4] [5] [6] . The incidence of VTE was estimated at 9-47% in COVID-19 patients hospitalized in intensive care units 4-10 and at [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] .8% in patients hospitalized in medical wards 7, 11, 12 . In contrast, some large retrospective studies did not observe a significant risk of VTE in hospitalized patients with COVID-19 12, 13 . Whether patients with mild and moderate COVID- 19 have a higher risk of VTE than similar patients with another disease and whether they require specific thromboprophylaxis are still matter of debate. The International Society of Thrombosis and Haemostasis (ISTH) suggests that "in the absence of COVID-19-specific data, it is reasonable to consider extended-duration thromboprophylaxis with Low-Molecular Weight Heparin (LMWH) or a Direct Oral Anticoagulant (DOAC) for at least 2 weeks and up to 6 weeks post-hospital discharge in selected COVID-19 patients who are at low risk for bleeding and with key VTE risk factors." 14, 15 . The American College of Chest Physician (ACCP) guidelines on the contrary suggest "inpatient thromboprophylaxis only over inpatient plus extended thromboprophylaxis after hospital discharge" 16 . Finally, to our knowledge, the rate of symptomatic VTE in patients with mild COVID-19 and who do not require hospitalization is unknown.

The aims of this study were to assess the rate and the risk factors of symptomatic VTE in patients with mild and moderate COVID-19 within the 28 days following an emergency department (ED) presentation, and to compare the VTE incidence in this COVID-19 cohort and in a prospective cohort of similar patients without COVID- 19. J o u r n a l P r e -p r o o f Journal Pre-proof

This study was a post-hoc analysis of a prospective multicenter cohort study of consecutive patients presenting to ED with mild and moderate COVID-19 and comparison with propensity score matching to another prospective cohort of similar patients who presented to the ED.

The STROBE (Strengthening the reporting of observational studies in epidemiology) checklist was followed (Appendix S1).

The first cohort of COVID-19 patients came from the HOME-CoV study 17 . The HOME-CoV study was a pragmatic prospective multicenter before/after design trial which aimed to validate the HOME-CoV rule 18 in triaging patients with confirmed or probable mild to moderate COVID-19 for home treatment. The first period was observational and the decision between hospitalization and home treatment was left up to the emergency physicians according to their current practices. During the interventional period, the physicians had to apply the HOME-CoV rule 18 . Patients were selected for home treatment if all criteria were negative, and for hospitalization otherwise. Patients who were managed at home were followed by their general practitioners without "hospital at home" facilities 17 . Patients were included, with their informed consent, if they had symptomatic COVID-19 confirmed by a positive SARS-CoV-2 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) or had typical symptoms of COVID-19 and COVID-19 was the most likely hypothesis according to the physician-in-charge. Screening by RT-PCR or performing a CT-scan were not systematic during patient management. Due to the low availability of RT-PCR tests at the time the study was performed, RT-PCR testing was not systematic and was mainly reserved for patients requiring hospitalization and/or when there was a diagnostic doubt. A CT-scan was performed in dyspneic patients as an alternative to chest X-ray and/or to exclude alternative diagnosis to COVID-19 pneumonia as acute pulmonary embolism. Patients with mild COVID-19 were defined as patients managed as outpatients. Patients with moderate COVID-19 J o u r n a l P r e -p r o o f Journal Pre-proof were defined as hospitalized patients without mechanical ventilation. Patients who required intensive care were excluded. Between April and May 2020, in 34 EDs (31 in France, 2 in Belgium and one in the Principality of Monaco), 3133 patients were included. Patients were followed up by phone at Day 7 and Day 28 and the occurrence of a VTE was recorded. The date of the VTE diagnosis and the examination to authenticate the VTE event were recorded to allow analysis over time. Data on the prescription of preventive anticoagulants were collected.

The comparison cohort came from the PERCEPIC study 19 . This trial was designed to prospectively assess the predictive value of a negative PERC to rule out pulmonary embolism (PE). The PERCEPIC study was a multicenter, prospective, observational study.

Participants were admitted in a participating ED with suspected PE (including dyspnea, chest pain, and other symptoms like syncope or hemoptysis) and had provided informed consent.

Between May 2015 to April 2016, 12 EDs (9 in France and 3 in Belgium) participated and 1757 patients were included. The occurrence of a VTE event was assessed at 90 days from admission to the ED, the day of VTE diagnosis and the examination to authenticate the VTE event were recorded. No data on the prescription of preventive anticoagulant was collected.

In both cohorts, patients were eligible for inclusion in the present study if they were admitted to the ED with acute dyspnea and/or chest pain and if they had undergone diagnostic testing for VTE in the ED: D-dimer test and/or Computed Tomography Pulmonary Angiogram (CTPA). The D-dimer threshold was adjusted for age, a level below agex10 ruling-out VTE in patients aged of fifty or more 20 . Patients for whom the diagnosis of VTE was established during the initial workup in the ED or within the 24 hours following ED presentation, and patients lost to follow up at Day 28 were excluded. The outcome was the rate of symptomatic VTE occurring within the 28 days following ED presentation. The diagnostic strategy was leave free to the physicians. A VTE was defined as a symptomatic PE objectively confirmed by CTPA or a ventilation-perfusion scan and/or a symptomatic deep venous thrombosis (DVT) confirmed by leg vein compression ultrasonography (CUS).

The outcome was compared between the COVID-19 cohort and the comparison cohort after adjustment using a weighting-based propensity score. Subgroup analysis were performed, using similar methods, according to the severity of symptoms and patients' management 

For descriptive analysis, quantitative variables were reported as mean ± standard deviation (SD) when their distribution can be considered as Gaussian, and with median and interquartile ranges (IQR) otherwise. Qualitative variables were reported using numbers and proportions. Comparisons were performed using Student or Mann-Whitney tests for quantitative variables and using the Fisher Exact test for qualitative variables. Weighting-based propensity scores (Inverse Probability Weighting) was performed using the average treatment effect among the overlap population (ATO), to balance covariates between the COVID-19 and comparison cohorts (Table S1 and Figure S1 ). Balance between groups was performed using the average treatment effect among the overlap population (ATO), which optimizes the efficiency of comparisons 21, 22 . Once the patient profiles have been balanced between the two cohorts, a logistic regression including a random effect on the center was performed enabling computation of the confidence interval for the difference in event rates between the two cohorts was performed. The first step was a superiority analysis of the COVID cohort on the primary outcome (i.e., VTE rate during the 28-day follow up). The absolute risk difference between groups and 95%CI was computed. Time-to-event curves were calculated by means of the Kaplan-Meier method. The Scaled-Schoenfeld residuals were computed to check the proportionality assumption. Statistical tests were performed to validate the nonproportionality combined with a plot of these residuals against time. The same methodology was used, and the propensity scores were recalculated in the moderate form of COVID-19 subgroup (i.e., hospitalized patients) and in the mild form of COVID-19 subgroup (i.e., outpatients) and according to the COVID-19 status. Censored data represent the end of follow-up at the time of ceasing the data collection. The hierarchization of objectives allowed us to avoid the problem of multiplicity as much as possible. However, when a problem of multiplicity was encountered, a correction of the p-values was carried out using the Holm procedure allowing a strong control of the Family Wise Error Rate (FWER) at 5% risk. Statistical analyses were performed using R software (version 3.5.1, R-Core Team) and the following R package: pec, WeigthIt packages and Survey and plotted by Kaplan-Meier curves.

The present study obtained approval from the ethics committee of the CHU of Angers (N°2020/87).

Among 3133 patients in the HOME-CoV study, 2292 patients were included in the COVID-19 cohort for the present study and 841 patients were excluded. The reasons for exclusion were as follows: 189 patients did not have dyspnea or chest pain at ED admission, 360 did not have a D-dimer assay or a CTPA performed and 221 were lost to follow-up at D28. Finally, 71 (2.3%) patients were excluded because of a confirmed PE during the initial workup. The characteristics of the patients included are summarized in Table 1 . 

In the COVID-19 cohort, the VTE rate within the 28 days following ED presentation was Lack of thromboprophylaxis was not a VTE risk factor. In the multivariate analysis, because the hospitalization and the D-dimer were collinear variables, they could not be taken together in the same model. Two models were developed (Table 2 ). In the first model, only an age over 65 was significantly associated with VTE. The D-dimer level was not a VTE risk factor. In the second model, an age over 65 was considered just about significant and the severity of the COVID-19 (moderate versus mild) was independently correlated to the VTE occurrence. Of 515 patients over 65 years of age with moderate COVID-19, 14 developed a VTE (14/515, 2.7%) including 5 patients who were receiving thromboprophylaxis treatment.

Of the 184 patients with an age over 65 treated at home, 2 developed a VTE (2/184, 1.1%).

Description of the comparison cohort A total of 1539 patients were included in the comparison cohort (Table 1) . From the initial PERCEPIC study population (n=1757 patients), a total of 218 patients were excluded: 11 did not have dyspnea or/and chest pain, 9 did not have a D-dimers assays or/and a CTPA, 198 patients were excluded because of a confirmed PE during the initial workup at the ED (11.3%) and 2 were lost to follow-up at D28. A total of 1068/1539 (69.5%) patients were treated at home. Conversely, the incidence in mild COVID-19 patients treated on an outpatient basis was low, below 1%, leaving no scope for systematic preventive anticoagulation. The challenge lies in defining which of them are at risk and require treatment. In this study, the two risk factors were hospitalization and an age over 65 years. Age is therefore both a risk factor for venous thrombosis and mortality in the case of COVID-19 3, 8, 28 . High levels of D-dimer did not correlate with the occurrence of VTE while this has been shown to be a prognostic factor in other studies 8, 29 . In any case, it is essential to assess the existence of a VTE concurrent with COVID-19 and to assess the thrombotic risk individually.

Our study is a post-hoc comparison of two large prospective multicentric cohorts. The centers. Finally, it was a retrospective comparison based on prospective data collected at different periods (2016 and 2020). To limit the differences between these two populations, we used strict inclusion criteria, i.e., only patients with dyspnea and/or chest pain, who had an initial diagnostic strategy for pulmonary embolism or deep vein thrombosis (i.e., at least D-dimer or CTPA) and in whom the hypothesis of VTE was ruled out were included. Thanks to a propensity score which considers a high number of variables, the adjusted populations were similar (Table S1 and Figure S1 ). We chose the ATO method which is the most reliable but requires a large population which we had available 30 . J o u r n a l P r e -p r o o f 

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: 

Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Outpatient Management of Patients With COVID-19: Multicenter Prospective Validation of the HOME-CoV Rule to safely discharge patients

Outpatient management or hospitalization of patients with proven or suspected SARS-CoV-2 infection: the HOME-CoV rule

Pulmonary embolism rule-out criteria (PERC) rule in European patients with low implicit clinical probability (PERCEPIC): a multicentre, prospective, observational study. The Lancet Haematology

Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients

Propensity Score Weighting for Causal Inference with Multiple Treatments

Balancing Covariates via Propensity Score Weighting

Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Pulmonary Embolism in Patients Hospitalized With COVID-19 (From a New York Health System)

Mortality and risk factors associated with pulmonary embolism in coronavirus disease 2019 patients: a systematic review and meta-analysis

Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners

*Including COPD stage III and IV and respiratory failure requiring daily oxygen therapy

Chronic cardiac failure including stage NYHA III-IV VTE: Venous Thromboembolism, IQR: interquartile Range; OR: Odds Ratio; 95%CI: 95% Confidence Interval